专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110230528A1 Use of Epothilone D in Treating Tau-Associated Diseases Including Alzheimer's Disease 有权
标题翻译：使用埃坡霉素D治疗包括阿尔茨海默氏病在内的au相关疾病
公开(公告)号：US20110230528A1
公开(公告)日：2011-09-22
申请号：US13150671
申请日：2011-06-01
申请人： Charles F. Albright , Donna Marie Barten , Francis Y. Lee
发明人： Charles F. Albright , Donna Marie Barten , Francis Y. Lee
IPC分类号： A61K31/427 , A61P25/28
CPC分类号： A61K31/427
摘要： Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.
摘要翻译：使用表现出良好的脑渗透性，长半衰期和脑中高选择性保留的埃坡霉素D来描述治疗Tau相关疾病，优选tau蛋白病的方法，并且提供有效治疗包括阿尔茨海默氏病在内的tau蛋白病的疗法。

2. 发明授权

US08673949B2 Use of epothilone D in treating Tau-associated diseases including Alzheimer's disease 有权
标题翻译：使用埃坡霉素D治疗包括阿尔茨海默病在内的Tau相关疾病
公开(公告)号：US08673949B2
公开(公告)日：2014-03-18
申请号：US13150671
申请日：2011-06-01
申请人： Charles F. Albright , Donna Marie Barten , Francis Y. Lee
发明人： Charles F. Albright , Donna Marie Barten , Francis Y. Lee
IPC分类号： A61K31/365 , A61K31/427 , C07D277/22
CPC分类号： A61K31/427
摘要： Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.
摘要翻译：使用表现出良好的脑渗透性，长半衰期和脑中高选择性保留的埃坡霉素D来描述治疗Tau相关疾病，优选tau蛋白病的方法，并且提供有效治疗包括阿尔茨海默氏病在内的tau蛋白病的疗法。

3. 发明申请

US20090270465A1 USE OF EPOTHILONE D IN TREATING TAU-ASSOCIATED DISEASES INCLUDING ALZHEIMER'S DISEASE 审中-公开
标题翻译：使用EPOTHILONE D治疗与TAI相关的疾病，包括阿尔茨海默病
公开(公告)号：US20090270465A1
公开(公告)日：2009-10-29
申请号：US12429492
申请日：2009-04-24
申请人： Charles F. Albright , Donna Marie Barten , Francis Y. Lee
发明人： Charles F. Albright , Donna Marie Barten , Francis Y. Lee
IPC分类号： A61K31/427
CPC分类号： A61K31/427
摘要： Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.
摘要翻译：使用表现出良好的脑渗透性，长半衰期和高选择性保留在脑中的埃坡霉素D来描述治疗Tau相关疾病，优选tau蛋白病的方法，并且提供治疗包括阿尔茨海默氏病在内的tau蛋白病的有效疗法。

4. 发明授权

US07608408B2 Methods of identifying compounds that inhibit Notch cleavage 有权
标题翻译：识别抑制Notch切割的化合物的方法
公开(公告)号：US07608408B2
公开(公告)日：2009-10-27
申请号：US11595721
申请日：2006-11-10
申请人： Catherine Burton , Charles F. Albright , Judith A. Wardwell-Swanson
发明人： Catherine Burton , Charles F. Albright , Judith A. Wardwell-Swanson
IPC分类号： C12Q1/68 , C07K14/435 , G01N33/53 , G01N33/68
CPC分类号： G01N33/566 , C07K14/705 , C12N5/0693 , C12N9/6421 , C12N2501/42 , C12N2503/02 , C12Q1/37 , G01N33/5008 , G01N2333/4725 , G01N2500/00
摘要： In vitro cell-based methods for identifying compounds that inhibit Notch cleavage and methods for identifying γ-secretase inhibitors that exhibit reduced induction of goblet cell metaplasia are provided. Also provided are methods of identifying compounds that inhibit cleavage of γ-secretase substrates other than Notch and homogeneous compositions or cultures of Notch-expressing cells that undergo mucin-2 or mucin-5AC induction in response to a compound known to inhibit Notch cleavage and methods of their generation.
摘要翻译：提供了用于鉴定抑制Notch切割的化合物的体外基于细胞的方法以及用于鉴定表现出减少的杯状细胞化生诱导的γ-分泌酶抑制剂的方法。还提供了鉴定抑制Notch切割γ分泌酶底物的化合物的方法，以及响应于已知抑制Notch切割的化合物进行粘蛋白-2或粘蛋白-5AC诱导的Notch表达细胞的均匀组合物或培养物的方法的一代。

5. 发明授权

US06844318B2 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use 有权
标题翻译：肽酶切割，靶向抗肿瘤药物及其治疗用途
公开(公告)号：US06844318B2
公开(公告)日：2005-01-18
申请号：US09808832
申请日：2001-03-15
申请人： Robert A. Copeland , Charles F. Albright , Andrew P. Combs , Randine L. Dowling , Nilsa R. Graciani , Wei Han , C. Anne Higley , Pearl S. Huang , Eddy W. Yue , Susan V. DiMeo
发明人： Robert A. Copeland , Charles F. Albright , Andrew P. Combs , Randine L. Dowling , Nilsa R. Graciani , Wei Han , C. Anne Higley , Pearl S. Huang , Eddy W. Yue , Susan V. DiMeo
IPC分类号： A61K31/704 , A61K38/00 , A61K47/48 , A61P35/00 , A61P35/02 , C07K5/02 , C07K5/04 , C07K5/117 , C07K7/06 , A61K38/07 , A61K38/08 , A61K38/14
CPC分类号： C07K7/06 , A61K38/00 , A61K47/65
摘要： This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in the targeted treatment of cancers.
摘要翻译：本发明涉及与包含膜结合和/或细胞分泌的肽酶的氨基酸识别序列的酶切割肽缀合的抗肿瘤剂，以及在靶向治疗癌症中使用这些缀合化合物作为化学治疗剂。

6. 发明授权

US3972945A Process for the selective synthesis of salicylaldehydes 失效
公开(公告)号：US3972945A
公开(公告)日：1976-08-03
申请号：US535895
申请日：1974-12-23
申请人： Charles F. Albright
发明人： Charles F. Albright
IPC分类号： C07C45/00
CPC分类号： C07C45/008
摘要： The classical Reimer-Tiemann reaction for the synthesis of phenolic aldehydes has been modified from an aqueous to a non-aqueous system to provide an improved route for the formation of salicylaldehydes and, preferably, 3-substituted salicylaldehydes, e.g. 3-fluorosalicylaldehyde. Heretofore, compounds such as 3-substituted salicylaldehydes have proven to be extremely difficult to prepare in other than small laboratory quantities from the corresponding ortho-substituted phenol, since, in the final salicylaldehyde, each position ortho to the hydroxyl group contains substitution. In particular, with respect to 3-fluorosalicylaldehyde, one of the positions is occupied by the strongly electronegative fluorine atom so that the principal reaction product in the aqueous Reimer-Tiemann reaction has always been the para-isomer (3-fluoro-4-hydroxy-benzaldehyde), only negligible quantities of the desired ortho-isomer being obtained. In the process of the present invention, o-fluorophenol is caused to react with sodium hydroxide and chloroform in a hydrocarbon diluent (preferably benzene), maintaining the reaction under essentially anhydrous conditions by taking up the water of reaction with excess sodium hydroxide. It is necessary that an aprotic solvent, such as N,N-dimethylformamide, be employed as a catalyst. The use of boron oxide, while not absolutely necessary to the reaction, has been found to be advantageous in that the reaction proceeds more smoothly if the phenoxyboroxine is formed initially. The boron oxide also acts as a dehydrating agent and aids in removing the water of reaction. The preferential reaction product is the desired 3-fluorosalicylaldehyde, no paraisomer having been found. After hydrolysis and neutralization, the 3-fluorosalicylaldehyde can be recovered by azeotropic distillation along with a substantial quantity of unreacted o-fluorophenol which can be purified for recycle in subsequent preparations.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式